French researchers have documented the first known human infection with Shamonda virus, a pathogen normally found in cattle, horses and sheep, and the patient died 16 days after neurological symptoms appeared. The case, reported by DongA Science and other Korean outlets, occurred on October 9 in a man in his 60s who lived in a rural part of the Rhône-Alpes region. A joint team from Lyon's civil hospital, the Lyon International Center for Infectious Disease Research (CIRI) and the French General Directorate of Health published its analysis in the journal Eurosurveillance on October 22.
Why it matters
Shamonda virus belongs to the orthobunyavirus group, and according to Nature's reporting on October 23, there is currently no vaccine or antiviral treatment approved for any orthobunyavirus. Crispin Heikowitz, a professor at the University of Queensland in Australia, told Nature that these viruses are known to infect animals such as cattle and deer and spread through mosquitoes and midges. DongA Science notes that specialists warn very little is known about what the virus does to the human body, which makes a fatal case worth close attention even if the patient's underlying condition shaped the outcome.
The virus has been circulating in European livestock since July, with clusters reported in France, Germany and Spain. Its jump into a person is the kind of event health agencies track because it shows a pathogen crossing from animals into humans, not because it signals an outbreak among people.
How the infection unfolded
The patient had leukemia and a severely weakened immune system, according to Nature. He began having seizures soon after symptoms started, then fell into a coma and was placed on mechanical ventilation. Doctors treated him with antibiotics, antivirals and high-dose corticosteroids, a class of drugs that dampens immune system activity to calm an overactive response. His condition did not improve, and the medical team stopped life-sustaining treatment.
The research team believes the man was most likely infected through a midge bite, based on evidence that Shamonda virus had already been detected in cattle in the Rhône-Alpes area. After his death, high concentrations of the virus were found in tissue samples from his brain, liver and spleen. The virus also turned up in his cerebrospinal fluid, and its genome closely resembled that of Shamonda virus isolated from animals.
The team's working explanation is that the man's suppressed immune system made the illness more severe. When the body's defenses are held back, a virus can persist longer and has a better chance of reaching the brain. That reasoning fits the sequence of events but remains an interpretation rather than a proven mechanism.
Five mutations and an open question
Comparison with animal-derived virus sequences turned up five genetic mutations in the virus taken from the patient that had not appeared in the animal samples. The researchers said it is not yet clear whether these changes make the virus better at infecting people. That question matters for risk assessment: a mutation that helps a virus enter human cells would be more concerning than one that has no effect.
On the question of spread between people, the team considers the risk low. Daniel Roll, who leads the emerging viral diseases laboratory at the QIMR Berghofer Medical Research Institute in Australia, told Nature that detections of orthobunyaviruses in humans are becoming more frequent. He pointed to climate change and growing contact among wildlife, livestock and people as factors raising the chance of human infection.
That framing places the French case in a broader pattern rather than treating it as an isolated accident. Land use, animal movement and shifting insect ranges all affect how often a livestock virus gets a chance to meet a person.
What to watch
The immediate next step is whether additional human cases are identified in the affected European regions and whether the five mutations found in this patient appear in any of them. French and international health bodies have not reported onward transmission, and the patient's immune status complicates any effort to generalize from a single death. For now, the record shows one fatal infection, a virus with no approved countermeasure, and a research community that says it still has much to learn about how Shamonda behaves in people.
